Acadia Pharma edges lower after sales top estimates

• Q4 net product sales of $12M topped estimates by nearly $3M.
• R&D expense of $30.2M vs. $20.5M a year ago; SG&A expense of $57.7M vs. $22.6 thanks to the sales force and costs from NUPLAZID.
• Cash and cash equivalents on hand as of Dec. 31 of $529M vs. $215.1M a year earlier.
• Conference call starts at 5 ET.
• Previously: ACADIA Pharma EPS in-line, beats on revenue (Feb. 28)
• ACAD -0.3% in active after hours action.
• SA Contributor George Rho has published an informative article on the company. He believes the stock still has plenty of upside.